Literature DB >> 17191900

Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells.

Wilairat Leeanansaksiri1, Shirley K DeSimone, Thomas Huff, Ewald Hannappel, Thomas F Huff.   

Abstract

Thymosin beta4 (Tbeta4), a 5 kDa polypeptide, is a member of the beta-thymosin family. It acts as the principal intracellular G-actin sequestering peptide and exhibits extracellular functions in angiogenesis and wound healing. The N-terminus of Tbeta4 contains a bioactive tetrapeptide, acSDKP, a negative regulator of hematopoietic stem-cell proliferation. Here, we show that both peptides inhibit mast-cell proliferation over the concentration range of 10(-6) to 10(-17) M with the maximum effect of both at 10(-14) M. Both Tbeta4 and acSDKP caused dysplastic mast-cell nuclei that were confirmed by DAPI fluorescent staining. Flow-cytometric analysis of ploidy revealed that the dysplastic nuclei were not multinucleated, but fragmented nuclei in G2 growth arrest. We could further demonstrate that 10(-8) or 10(-14) M Tbeta4 or acSDKP induce mast-cell degranulation. A concentration of 10(-8) M Tbeta4 or acSDKP caused 57 or 89% degranulation, respectively. A number of tryptic fragments of Tbeta4 were assayed beside intact Tbeta4 and the tetrapeptide, and found to be inactive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 17191900     DOI: 10.1002/cbdv.200490081

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  5 in total

1.  Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK.

Authors:  Ping Qiu; Michelle Kurpakus Wheater; Yue Qiu; Gabriel Sosne
Journal:  FASEB J       Date:  2011-02-22       Impact factor: 5.191

2.  Exogenous thymosin beta4 prevents apoptosis in human intervertebral annulus cells in vitro.

Authors:  H Tapp; R Deepe; J A Ingram; E G Yarmola; M R Bubb; E N Hanley; H E Gruber
Journal:  Biotech Histochem       Date:  2009-12       Impact factor: 1.718

3.  Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Authors:  Jo Caers; Dirk Hose; Ine Kuipers; Tomas Jan Bos; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Hartmut Goldschmidt; Ben Van Camp; Bernard Klein; Karin Vanderkerken
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

4.  Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.

Authors:  Gabriel Sosne; Ping Qiu; Michelle Kurpakus-Wheater
Journal:  Clin Ophthalmol       Date:  2007-09

Review 5.  Thymosin beta4 and Ac-SDKP: tools to mend a broken heart.

Authors:  Alex Rossdeutsch; Nicola Smart; Paul R Riley
Journal:  J Mol Med (Berl)       Date:  2007-08-15       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.